These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 18424129

  • 1. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97.
    Schmidt M, Simon T, Hero B, Schicha H, Berthold F.
    Eur J Cancer; 2008 Jul; 44(11):1552-8. PubMed ID: 18424129
    [Abstract] [Full Text] [Related]

  • 2. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.
    Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, Bongartz R, Berthold F, Schicha H.
    Nuklearmedizin; 2006 Jul; 45(4):145-51; quiz N39-40. PubMed ID: 16964339
    [Abstract] [Full Text] [Related]

  • 3. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study.
    Decarolis B, Schneider C, Hero B, Simon T, Volland R, Roels F, Dietlein M, Berthold F, Schmidt M.
    J Clin Oncol; 2013 Mar 01; 31(7):944-51. PubMed ID: 23341514
    [Abstract] [Full Text] [Related]

  • 4. Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma.
    Claudiani F, Stimamiglio P, Bertolazzi L, Cabria M, Conte M, Villavecchia GP, Garaventa A, Lanino E, De Bernardi B, Scopinaro G.
    Q J Nucl Med; 1995 Dec 01; 39(4 Suppl 1):21-4. PubMed ID: 9002744
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Can MIBG scan replace the need for bone marrow assessment at diagnosis and reassessment in stage 4 neuroblastomas?
    Frappaz D, Combaret V, Desuzinges C, Bouffet E, Bailly C, Favrot MC, Philip T.
    Bull Cancer; 2004 Dec 01; 91(7-8):E253-60. PubMed ID: 15381463
    [Abstract] [Full Text] [Related]

  • 10. [Metaiodobenzylguanidine scintigraphy in the diagnosis and followup of neuroblastoma. Apropos of 16 cases].
    Hammami H, Hassine L, Mhiri A, Sellem A, Oubich F, Gharssallah L, Barsaoui S, Ben Brahim H.
    Tunis Med; 2007 May 01; 85(5):413-6. PubMed ID: 17657930
    [Abstract] [Full Text] [Related]

  • 11. 131I-MIBG in the diagnosis of primary and metastatic neuroblastoma.
    El-Maghraby T.
    Gulf J Oncolog; 2007 Jul 01; (2):33-41. PubMed ID: 20084722
    [Abstract] [Full Text] [Related]

  • 12. Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma.
    Katzenstein HM, Cohn SL, Shore RM, Bardo DM, Haut PR, Olszewski M, Schmoldt J, Liu D, Rademaker AW, Kletzel M.
    J Clin Oncol; 2004 Oct 01; 22(19):3909-15. PubMed ID: 15459212
    [Abstract] [Full Text] [Related]

  • 13. Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease.
    Simon T, Hero B, Bongartz R, Schmidt M, Müller RP, Berthold F.
    Strahlenther Onkol; 2006 Jul 01; 182(7):389-94. PubMed ID: 16826357
    [Abstract] [Full Text] [Related]

  • 14. Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma.
    Polishchuk AL, Li R, Hill-Kayser C, Little A, Hawkins RA, Hamilton J, Lau M, Tran HC, Strahlendorf C, Lemons RS, Weinberg V, Matthay KK, DuBois SG, Marcus KJ, Bagatell R, Haas-Kogan DA.
    Int J Radiat Oncol Biol Phys; 2014 Jul 15; 89(4):839-45. PubMed ID: 24867534
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. The SFOP Group.
    Frappaz D, Bonneu A, Chauvot P, Edeline V, Giammarile F, Siles S, Wioland M, Gomez F.
    Med Pediatr Oncol; 2000 Apr 15; 34(4):237-41. PubMed ID: 10742058
    [Abstract] [Full Text] [Related]

  • 17. The role of 99Tcm-sestamibi scintigraphy in the staging and prediction of the therapeutic response of stage IV neuroblastoma: comparison with 131I-MIBG and 99Tcm-MDP scintigraphy.
    Burak Z, Yüksel DA, Cetingül N, Kantar M, Ozkiliç H, Moretti JL.
    Nucl Med Commun; 1999 Nov 15; 20(11):991-1000. PubMed ID: 10572908
    [Abstract] [Full Text] [Related]

  • 18. Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group.
    Naranjo A, Parisi MT, Shulkin BL, London WB, Matthay KK, Kreissman SG, Yanik GA.
    Pediatr Blood Cancer; 2011 Jul 01; 56(7):1041-5. PubMed ID: 21328522
    [Abstract] [Full Text] [Related]

  • 19. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma.
    Perel Y, Conway J, Kletzel M, Goldman J, Weiss S, Feyler A, Cohn SL.
    J Pediatr Hematol Oncol; 1999 Jul 01; 21(1):13-8. PubMed ID: 10029806
    [Abstract] [Full Text] [Related]

  • 20. Nuclear medicine procedures and neuroblastoma in childhood. Their value in the diagnosis, staging and assessment of response to therapy.
    Boubaker A, Bischof Delaloye A.
    Q J Nucl Med; 2003 Mar 01; 47(1):31-40. PubMed ID: 12714952
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.